VIP943: Preliminary data from P1 trial (NCT06034275) for advanced CD123+ hematologic malignancies in mid-2024 (Vincerx Pharma) - Mar 5, 2024 - Corporate Presentation
P1 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology
|